Why Is Axsome (AXSM) Up 19.2% Since Last Earnings Report?

Axsome Therapeutics (AXSM) shares have gained 19.2% since its last earnings report, outperforming the S&P 500, following a Q2 2025 performance that beat expectations. The company reported a narrower adjusted loss of $0.97 per share and total revenues of $150 million, a 72% year-over-year increase, primarily driven by robust Auvelity sales of $119.6 million, up 84% year-over-year. Despite this strong operational showing, analyst estimates for AXSM have shown a downward trend, resulting in a Zacks Rank #3 (Hold).

Analysis

Axsome Therapeutics (AXSM) delivered a strong second-quarter performance, highlighted by a significant revenue beat and a narrower-than-expected loss, which catalyzed a 19.2% share price increase, outperforming the S&P 500. Total revenues surged 72% year-over-year to $150 million, surpassing consensus estimates of $140 million, while the adjusted loss per share improved to $0.97 from $1.67 in the prior-year quarter. This top-line strength was primarily driven by the exceptional commercial uptake of its drug Auvelity, which saw sales grow 84% year-over-year to $119.6 million, with prescriptions increasing 56% YoY. The company's operational focus is clearly shifting towards commercialization, evidenced by a 25.8% rise in SG&A expenses to support its portfolio, alongside a slight decrease in R&D spending. However, a critical disconnect exists between this robust operational momentum and forward-looking sentiment. Despite the strong quarterly results, analyst earnings estimates have been trending downwards, leading to a neutral Zacks Rank #3 (Hold) and a poor 'F' score for value, suggesting concerns about the sustainability of this growth or the path to profitability.

Key Decisions for Investors

• Given the strong commercial execution and 84% YoY sales growth of Auvelity, investors with a high-risk tolerance may interpret the recent 19.2% share price rally as a validation of the company's growth trajectory and could view the subsequent downward analyst revisions as a potential entry point if momentum continues.
• Investors should exercise caution due to the noted downward trend in analyst earnings estimates and the neutral 'Hold' rating, which conflict with the recent stock performance and could signal underlying concerns about future profitability or market saturation.
• Monitor upcoming reports for continued sequential growth in Auvelity and Sunosi prescriptions, the initial sales ramp of the new drug Symbravo, and management's ability to control SG&A expenses, as these factors will be critical in determining the company's ability to translate revenue growth into profitability.